PMGC Holdings (ELAB) Finished Goods (2023 - 2026)

PMGC Holdings (ELAB) posted Finished Goods of $107562.0 for Q1 2026, up 26.4% sequentially from $85098.0 in Q4 2025.

PMGC Holdings (ELAB) Finished Goods (2023 - 2026) Analysis & Trends

PMGC Holdings has reported Finished Goods for 4 years, with the latest figure at $107562.0 in Q1 2026.

Quarterly Finished Goods changed N/A year-over-year to $107562.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $107562.0 (changed N/A YoY) and the FY2025 annual result came in at $85098.0, changed N/A from the prior year.
Finished Goods grew to $107562.0 in Q1 2026 per ELAB's latest filing, from $85098.0 in the prior quarter.
Over five years, Finished Goods peaked at $329913.0 in Q1 2024 and troughed at $68247.0 in Q4 2023.
A 4-year average of $170230.4 and a median of $128469.0 in 2025 frame the typical range for Finished Goods.
The widest YoY moves for Finished Goods: up 50.2% in 2025, down 50.2% in 2025.
Over 4 years, Finished Goods stood at $68247.0 in 2023, then surged by 278.01% to $257980.0 in 2024, then plunged by 67.01% to $85098.0 in 2025, then rose by 26.4% to $107562.0 in 2026.
According to Business Quant data, Finished Goods over the past three periods registered $107562.0, $85098.0, and $128469.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.99 Bn	132.14 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.80 Bn	78.80 Bn	3.93 Bn
3	Argenx Se	65.38 Bn	60.19 Bn	1.37 Bn
4	Moderna	60.70 Bn	55.56 Bn	52.00 Mn
5	BeOne Medicines	42.22 Bn	37.12 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.67 Bn	28.36 Bn	992.69 Mn
7	BioNTech SE	28.45 Bn	10.06 Bn	668.28 Mn
8	Insmed	27.47 Bn	26.31 Bn	358.27 Mn
9	Royalty Pharma	27.21 Bn	26.37 Bn	-
10	PMGC Holdings	29.60 Mn	10.81 Mn	385,691.00

Download Data